上市公司資料
 
深圳市海普瑞藥業集團股份有限公司 股票代號:  09989
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 集團網址: http://www.hepalink.com
損益表
  2025/12
RMB(K$)
變動 2024/12
RMB(K$)
2023/12
RMB(K$)
營業額5,438,2563.410%5,258,9195,430,974
經營溢利/(虧損)400,699-53.839%868,049(480,383)
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)1,541--(141,820)(447,951)
稅前溢利/(虧損)402,240-44.613%726,229(928,334)
稅項(59,604)--(101,311)126,175
少數股東權益6,850-68.613%21,82418,901
股東應佔溢利/(虧損)349,486-45.962%646,742(783,258)
 
淨利息收入/(支出)(32,552)--(93,426)(183,698)
折舊與攤銷376,72112.485%334,909377,848
董事酬金----12,92911,870
 
每股盈利/(虧損)(仙)24.000-45.455%44.000(53.000)
每股派息(仙)14.500-42.000%25.0000.000
 
派息比率(%)60.417%--56.818%--
每股帳面資產淨值($)8.199-0.969%8.2808.119
主要財務比率
  2025/12
RMB(K$)
變動 2024/12
RMB(K$)
2023/12
RMB(K$)
經營邊際利潤率(%)7.368%--16.506%(8.845)%
利息盈利率(x)6.382--6.144--
資產回報率(%)2.057%--3.539%(3.914)%
股東資金回報率(%)2.891%--5.376%(6.466)%

 

Copyright © 2026 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.